These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 31138176

  • 1. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    Kettunen E, Savukoski S, Salmenkivi K, Böhling T, Vanhala E, Kuosma E, Anttila S, Wolff H.
    BMC Cancer; 2019 May 28; 19(1):507. PubMed ID: 31138176
    [Abstract] [Full Text] [Related]

  • 2. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.
    Hum Pathol; 2017 Feb 28; 60():86-94. PubMed ID: 27771374
    [Abstract] [Full Text] [Related]

  • 3. Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.
    Sarun KH, Lee K, Williams M, Wright CM, Clarke CJ, Cheng NC, Takahashi K, Cheng YY.
    Int J Mol Sci; 2018 Oct 07; 19(10):. PubMed ID: 30301262
    [Abstract] [Full Text] [Related]

  • 4. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G, Özekinci S.
    Eur Rev Med Pharmacol Sci; 2023 Oct 07; 27(20):10001-10007. PubMed ID: 37916370
    [Abstract] [Full Text] [Related]

  • 5. Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).
    Chernova T, Murphy FA, Galavotti S, Sun XM, Powley IR, Grosso S, Schinwald A, Zacarias-Cabeza J, Dudek KM, Dinsdale D, Le Quesne J, Bennett J, Nakas A, Greaves P, Poland CA, Donaldson K, Bushell M, Willis AE, MacFarlane M.
    Curr Biol; 2017 Nov 06; 27(21):3302-3314.e6. PubMed ID: 29112861
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, Fujino M, Yamakawa H, Nakatani Y, Tada Y, Shimada H, Tagawa M.
    Am J Clin Pathol; 2013 Jan 06; 139(1):39-46. PubMed ID: 23270897
    [Abstract] [Full Text] [Related]

  • 7. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T, Hatanaka Y, Marukawa K, Okada H, Hatanaka KC, Sakakibara-Konishi J, Oizumi S, Hida Y, Kaga K, Mitsuhashi T, Matsuno Y.
    Diagn Pathol; 2016 Apr 18; 11():38. PubMed ID: 27091358
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
    Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H.
    Virchows Arch; 2008 Dec 18; 453(6):627-35. PubMed ID: 18958493
    [Abstract] [Full Text] [Related]

  • 9. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
    Chirac P, Maillet D, Leprêtre F, Isaac S, Glehen O, Figeac M, Villeneuve L, Péron J, Gibson F, Galateau-Sallé F, Gilly FN, Brevet M.
    Hum Pathol; 2016 Sep 18; 55():72-82. PubMed ID: 27184482
    [Abstract] [Full Text] [Related]

  • 10. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
    Andujar P, Wang J, Descatha A, Galateau-Sallé F, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Renier A, Zucman-Rossi J, Pairon JC, Jaurand MC.
    Lung Cancer; 2010 Jan 18; 67(1):23-30. PubMed ID: 19375815
    [Abstract] [Full Text] [Related]

  • 11. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S, Dick I, Lee YCG, Musk AWB, Patch AM, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J.
    Lung Cancer; 2018 May 18; 119():64-70. PubMed ID: 29656754
    [Abstract] [Full Text] [Related]

  • 12. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A, Prabhakaran S, Pulford E, Hocking AJ, Godbolt D, Ziad F, Pandita A, Wessels A, Hussey M, Russell PA, Klebe S.
    Pathology; 2024 Aug 18; 56(5):662-670. PubMed ID: 38789301
    [Abstract] [Full Text] [Related]

  • 13. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
    Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS.
    J Clin Pathol; 2010 Jul 18; 63(7):630-4. PubMed ID: 20591913
    [Abstract] [Full Text] [Related]

  • 14. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K.
    Cancer Sci; 2015 Nov 18; 106(11):1635-41. PubMed ID: 26291840
    [Abstract] [Full Text] [Related]

  • 15. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima K, Kawahara K, Sato A, Tsujimura T, Nakatani Y, Yoshida Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2016 Sep 18; 99():155-61. PubMed ID: 27565933
    [Abstract] [Full Text] [Related]

  • 16. Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats.
    Okazaki Y, Misawa N, Akatsuka S, Kohyama N, Sekido Y, Takahashi T, Toyokuni S.
    Cancer Sci; 2020 Apr 18; 111(4):1180-1192. PubMed ID: 32080953
    [Abstract] [Full Text] [Related]

  • 17. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM, Bartlett DL, Cieply K, Dacic S.
    Mod Pathol; 2010 Apr 18; 23(4):531-8. PubMed ID: 20081810
    [Abstract] [Full Text] [Related]

  • 18. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S.
    Mod Pathol; 2020 Feb 18; 33(2):217-227. PubMed ID: 31570769
    [Abstract] [Full Text] [Related]

  • 19. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Pathol Int; 2016 Oct 18; 66(10):563-570. PubMed ID: 27614970
    [Abstract] [Full Text] [Related]

  • 20. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB, Dubuc AM, Hornick JL, Sholl LM.
    Histopathology; 2021 Jun 18; 78(7):1032-1042. PubMed ID: 33387364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.